Petersson J, Giske C G, Eliasson E
Function Perioperative Medicine and Intensive Care, Karolinska University Hospital Solna, Stockholm, Sweden
Section of Anesthesiology and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02029-20.
There is insufficient data on the relationship between antibiotic dosing and plasma concentrations in patients treated with continuous renal replacement therapy (CRRT). In this prospective observational study, we explored the variability in plasma concentrations of meropenem and piperacillin in critically ill patients treated with CRRT and the correlation between concentrations and CRRT intensity. Antibiotic concentrations were measured at the middle and end of the dosing interval and repeated after 2 to 3 days when feasible. Measured concentrations were compared to the clinical susceptible breakpoints for , 16 and 2 mg/liter for piperacillin and meropenem, respectively. CRRT intensity was estimated by delivered, time-averaged, total effluent flow (), corrected for predilution. Concentrations were also compared between patients with different residual diuresis. We included 140 meropenem concentrations from 98 patients and 47 piperacillin concentrations from 37 patients. Concentrations at the middle of the dosing interval were above target at all occasions for both antibiotics. For meropenem, 6.5% of trough concentrations were below target, and for piperacillin, 22%. Correlations between and antibiotic concentrations or the concentration half-life () were either statistically not significant or weak. Meropenem concentrations and values differed between patients with different residual diuresis. Thus, when treating intensive care patients with CRRT and recommended doses of meropenem or piperacillin, both low, suboptimal plasma concentrations and unnecessarily high, potentially toxic, plasma concentrations are common. Plasma concentrations cannot be predicted from CRRT intensity. Residual diuresis is associated with lower meropenem concentrations, but the correlation is weak. Concentration measurement is probably the most useful approach to avoid suboptimal treatment.
关于接受持续肾脏替代治疗(CRRT)的患者抗生素剂量与血浆浓度之间的关系,目前数据不足。在这项前瞻性观察研究中,我们探讨了接受CRRT治疗的重症患者美罗培南和哌拉西林血浆浓度的变异性以及浓度与CRRT强度之间的相关性。在给药间隔的中期和末期测量抗生素浓度,并在可行的情况下于2至3天后重复测量。将测得的浓度与哌拉西林和美罗培南的临床敏感断点分别为16和2毫克/升进行比较。通过输送的、时间平均的总流出量()估算CRRT强度,并对预稀释进行校正。还比较了不同残余尿量患者之间的浓度。我们纳入了98例患者的140个美罗培南浓度和37例患者的47个哌拉西林浓度。两种抗生素在给药间隔中期的浓度在所有情况下均高于目标值。对于美罗培南,6.5%的谷浓度低于目标值,对于哌拉西林,这一比例为22%。与抗生素浓度或浓度半衰期()之间的相关性在统计学上要么不显著,要么较弱。不同残余尿量患者的美罗培南浓度和值存在差异。因此,在用CRRT和推荐剂量的美罗培南或哌拉西林治疗重症监护患者时,血浆浓度低、未达最佳水平以及不必要地高、可能有毒的情况都很常见。无法根据CRRT强度预测血浆浓度。残余尿量与较低的美罗培南浓度相关,但相关性较弱。浓度测量可能是避免治疗未达最佳水平的最有用方法。